Advances in pharmacogenetics of systemic therapies for psoriasis

Abstract

Abstract: Psoriasis is an inflammatory hyperproliferative skin disease with a strong genetic susceptibility and influenced by genetic, immunological and environmental factors. Because most patients with moderate to severe psoriasis cannot benefit from the topical treatment, they have to treat with systemic agents. While the systemic treatment is characterized of high medical cost and large inter-individual variations in efficacy and adverse reaction, the studies on pharmacogenetics of systemic therapies for Psoriasis play an important role in clinic.This review summarizes the correlations between genetic factors and systemic agents to provide the theoretical guidance for the personalized medication in psoriasis.

Key words: Psoriasis, Pharmacogenetics, Methotrexate, Cyclosporine A, Acitretin

CLC Number:

R751.05

MENG Xiang-guang, NI Wen-qiong, WANG Chao, MA Deng-xuan, LI Zhi, ZHOU Hong-hao. Advances in pharmacogenetics of systemic therapies for psoriasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1307-1313.

References

[1] 张学军. 全基因组关联分析对银屑病遗传学研究的启示[J]. 浙江大学学报:医学版, 2009,38(4): 333-337.
[2] Henseler T, Christophers E.Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris[J].J Am Acad Dermatol,1985,13(3): 450-456.
[3] Lebwohl M.Psoriasis[J].Lancet,2003,361(9364): 1197-1204.
[4] Yip SY.The prevalence of psoriasis in the Mongoloid race[J].J Am Acad Dermatol,1984,10(6): 965-968.
[5] Braathen LR, Botten G, Bjerkedal T.Prevalence of psoriasis in Norway[J].Acta Derm Venereol Suppl (Stockh),1989,142: 5-8.
[6] Zhang XJ, Huang W, Yang S, et al.Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21[J].Nat Genet,2009,41(2): 205-210.
[7] Duffy DL, Spelman LS, Martin NG.Psoriasis in Australian twins[J].J Am Acad Dermatol,1993,29(3): 428-434.
[8] O'Rielly DD, Rahman P. Pharmacogenetics of psoriasis[J].Pharmacogenomics,2011,12(1): 87-101.
[9] 张伟,贺毅憬,周宏灏. 有机阴离子转运多肽1B1的遗传药理学进展[J]. 中国临床药理学与治疗学,2008,13(7): 721-729.
[10] 单婷婷,董瑞华,秦小清,等. 药物基因多态性与个体化用药的研究进展[J]. 医药导报,2010,29(1): 64-67.
[11] Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review[J].Australas J Dermatol,2012,53(1): 1-18.
[12] Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis[J].Br J Dermatol,1994,130(2): 204-210.
[13] Heydendael VM, Spuls PI, Opmeer BC, et al.Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J].N Engl J Med,2003,349(7): 658-665.
[14] Flytstrom I, Stenberg B, Svensson A, et al.Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J].Br J Dermatol,2008,158(1): 116-121.
[15] Ryan C, Menter A, Warren RB.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis[J].Mol Diagn Ther,2010,14(2): 81-93.
[16] Campalani E, Arenas M, Marinaki AM, et al.Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis[J].J Invest Dermatol,2007,127(8): 1860-1867.
[17] Warren RB, Smith RL, Campalani E, et al.Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis[J].J Invest Dermatol,2008,128(8): 1925-1929.
[18] Frosst P, Blom HJ, Milos R, et al.A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase[J].Nat Genet,1995,10(1): 111-113.
[19] Fisher MC, Cronstein BN.Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity[J].J Rheumatol,2009,36(3): 539-545.
[20] Horie N, Aiba H, Oguro K, et al.Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase[J].Cell Struct Funct,1995,20(3): 191-197.
[21] Kumagai K, Hiyama K, Oyama T, et al.Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis[J].Int J Mol Med,2003,11(5): 593-600.
[22] Warren RB, Smith RL, Campalani E, et al.Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms[J].Br J Dermatol,2009,160(2): 438-441.
[23] Hider SL, Thomson W, Mack LF, et al.Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX[J].Rheumatology (Oxford),2008,47(8): 1156-1159.
[24] Gottlieb AB, Krueger JG, Khandke L, et al.Role of T cell activation in the pathogenesis of psoriasis[J].Ann N Y Acad Sci,1991,636: 377-379.
[25] Haider AS, Lowes MA, Suarez-Farinas M, et al.Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis[J].J Immunol,2008,180(3): 1913-1920.
[26] Young HS, Summers AM, Read IR, et al.Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis[J].J Invest Dermatol,2006,126(2): 453-459.
[27] Lebwohl M, Christophers E, Langley R, et al.An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis[J].Arch Dermatol,2003,139(6): 719-727.
[28] Haider AS, Lowes MA, Gardner H, et al.Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients[J].J Immunol,2007,178(11): 7442-7449.
[29] O'Rielly DD, Roslin NM, Beyene J, et al. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis[J].Pharmacogenomics J,2009,9(3): 161-167.
[30] Gottlieb AB, Chamian F, Masud S, et al.TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques[J].J Immunol,2005,175(4): 2721-2729.
[31] Croxtall JD.Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis[J].Drugs,2011,71(13): 1733-1753.
[32] Chen X, Tan Z, Yue Q, et al.The expression of interleukin-23 (p19/p40) and inteleukin-12 (p35/p40) in psoriasis skin[J].J Huazhong Univ Sci Technolog Med Sci,2006,26(6): 750-752.
[33] Toichi E, Torres G, Mccormick TS, et al.An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis[J].J Immunol,2006,177(7): 4917-4926.